The translation of MOFs into clinical applications requires the design of biocompatible MOFs. Indeed, new drug delivery systems must be de-risked as soon as possible to facilitate successful clinical translation. While experiments are resource and time-intensive, classical modelling approaches fail to capture the behavior of MOFs in biological systems and, therefore, the fundamental understanding of what makes a MOF biocompatible or toxic. From our investigations, the key insights include: